The startup specializes in genome engineering and chromatin regulation technologies to enable targeted gene editing in vivo. By providing methods for the insertion of any-length genetic sequences into the human genome, the company aims to develop permanent cures for genetic diseases.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current genome engineering techniques face challenges in delivering large genetic payloads with precision and without causing double-stranded breaks, hindering the development of effective in vivo gene therapies. Existing methods often lack the capacity for complex, multigenic therapeutic payloads needed to address many diseases.
Solution
Stylus Medicine is developing in vivo genetic medicines using engineered recombinases to enable targeted insertion of any-length genetic sequences into the human genome. Their platform utilizes a novel class of enzymes designed to recognize a safe harbor site in the genome and introduce therapeutic payloads with high specificity and integrity. By leveraging cell-targeted lipid nanoparticles (LNPs), Stylus Medicine aims to deliver therapeutic payloads directly to immune cells in vivo, with an initial focus on creating in vivo CAR-T therapies. This approach has the potential to transform patient treatment, improve accessibility, and redefine possibilities in medicine across oncology, autoimmune diseases, genetic disorders, and beyond.
Target Audience
The primary target audience includes patients with genetic diseases, cancer, and autoimmune disorders, as well as pharmaceutical companies and research institutions focused on developing in vivo gene therapies and CAR-T cell therapies.
Features
- Engineered recombinases for targeted, sequence-specific introduction of therapeutic payloads
- Reproducible and predictable insertional profile without exposed double-stranded breaks
- High capacity for large, complex, multigenic therapeutic payloads
- Cell-targeted lipid nanoparticle (LNP) delivery for in vivo genetic medicines
- Versatile and modular approach applicable across oncology, autoimmune diseases, and genetic disorders